Core Viewpoint - The company, Jian Shi Technology-B (09877), has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system Ken-Valve and transcatheter tricuspid valve replacement system LuX-ValvePlus, which will accelerate the global commercialization of its product portfolio [1][5]. Group 1 - Jian Shi Technology-B's stock price initially rose over 8% in the morning but later adjusted to a slight increase of 0.24%, trading at HKD 8.50 with a transaction volume of HKD 3.4321 million [1][5]. - The company is actively promoting the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following their recent registration approval [1][5]. - The announcement highlights that the products have gained broad market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1][5].

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 本文源自：智通财经网 智通财经获悉，健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港元。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 ...

经济观察网 2026年2月25日，赛诺医疗(688108)发布公告，公司拟1500万元至3000万元回购股份，回购 价格不超过35.1元/股。 ...

截至2026年2月26日 09:56，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 4.59%，爱博医疗上涨2.03%，锦波生物上涨0.40%；惠泰医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近3天获得连续资金净流入，最高单日获得617.32万元净流入， 合计"吸金"1269.71万元，日均净流入达423.24万元。（数据来源：Wind） 消息面上，2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方 NextPharma数据库显示，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件， 首付款约为31.23亿美元，总金额达532.76亿美元。 江海证券指出，2026年中国创新药BD呈现三大转型：技术输出联合产品授权、平台化合作、全球并跑 创新。建议关注小核酸（递送技术/慢病管线）、肿瘤免疫（双抗/ADC联用）、代谢疾病（GLP-1改良 品种/MASH肝靶向siRNA）、CGT（体内基因编辑/通用型CAR-T）等核心赛道，重点评估平台造血能 力（如年输出管线数）、临床里 ...

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 智通财经APP获悉，健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港 元。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 ...

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港元。 ...

资料显示，济民健康管理股份有限公司位于浙江省台州市黄岩区北院路888号，成立日期1996年12月24 日，上市日期2015年2月17日，公司主营业务涉及医疗器械的研发、生产和销售,医疗服务,以及大输液产 品研发、生产和销售。主营业务收入构成为：医药制造52.07%，医疗服务46.01%，医药贸易1.54%，其 他(补充)0.38%。 截至9月30日，济民健康股东户数5.81万，较上期增加107.00%；人均流通股9035股，较上期减少 51.69%。2025年1月-9月，济民健康实现营业收入5.45亿元，同比减少20.21%；归母净利润-7715.04万 元，同比减少371.51%。 2月25日，济民健康涨1.68%，成交额7577.07万元。两融数据显示，当日济民健康获融资买入额400.17 万元，融资偿还379.04万元，融资净买入21.13万元。截至2月25日，济民健康融资融券余额合计1.69亿 元。 融资方面，济民健康当日融资买入400.17万元。当前融资余额1.69亿元，占流通市值的3.55%，融资余 额低于近一年20%分位水平，处于低位。 融券方面，济民健康2月25日融券偿还0.00股，融券卖出3 ...

分红方面，三诺生物A股上市后累计派现15.12亿元。近三年，累计派现3.44亿元。 融券方面，三诺生物2月25日融券偿还2500.00股，融券卖出600.00股，按当日收盘价计算，卖出金额 1.09万元；融券余量12.05万股，融券余额219.19万元，超过近一年90%分位水平，处于高位。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路265号，成立日期 2002年8月7日，上市日期2012年3月19日，公司主营业务涉及以生物传感技术为基础的相关慢性疾病即 时检测(POCT)产品的研发、设计、生产和销售。主营业务收入构成为：血糖监测系统73.29%，糖尿病 营养、护理等辅助产品6.59%，糖化血红蛋白检测系统5.03%，血脂检测系统4.14%，血压计4.11%， iPOCT监测系统3.94%，经营品2.05%，其他0.85%。 截至9月30日，三诺生物股东户数2.46万，较上期增加58.52%；人均流通股18347股，较上期减少 37.47%。2025年1月-9月，三诺生物实现营业收入34.53亿元，同比增长8.52%；归母净利润2.11亿元，同 比减少17.36%。 2月25日，三 ...

Core Insights - Zhengzhou is set to host over 10 exhibitions in March, covering diverse sectors such as education, retail, and catering, aimed at enhancing economic and trade cooperation and promoting industrial collaboration for high-quality development in the region [1][2]. Group 1: Exhibition Schedule - The "Great Instruments · Great Journey 2026 China (Zhengzhou) Aerospace National Defense Science Popularization Carnival" will take place from March 1 to 4 [2]. - The "China Zhengzhou Retail Supply Chain Exhibition and China Zhengzhou Retail Private Brand Exhibition" along with the "Zhengzhou Supermarket Processed Food Exhibition" is scheduled for March 6 to 7 [2]. - The "Second Henan Education Logistics Expo and School-Enterprise Docking Conference" and the "Second Henan Smart Group Meal and Catering Supply Chain Expo" will occur from March 6 to 8 [2]. - The "2026 China Hair Products Spring Trading Fair" is set for March 16 to 18 [2]. - The "2026 Spring (Zhengzhou) 45th Central Plains Advertising Exhibition" and the "2026 Central China (Zhengzhou) Decorative Painting and Frame and Soft Decoration Exhibition" will be held from March 18 to 20 [2]. - The "7th China Health Industry Brand Exhibition" is scheduled for March 19 to 20 [2]. - The "48th Central Plains Medical Devices (Spring 2026) Exhibition" and the "2026 Central China Dental (Zhengzhou) Equipment and Materials Exhibition" will take place from March 23 to 25 [2]. - The "38th Huaxia Home Expo" and the "23rd Central Plains Agricultural Products Trading and Information Exchange Conference" are set for March 28 to 29 [2]. - The "24th China (Zhengzhou) Education Innovation Conference" and the "24th China (Zhengzhou) Education Project Franchise and Education Technology Exhibition" along with the "2026 (China) Zhengzhou Digital Industry Expo and the 17th Central and Western IT Products Expo" and the "China (Zhengzhou) Consumer Electronics Expo" will be held from March 31 to April 2 [2].

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]